Adam Graham Stewart, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enterobacteriaceae Infections | 5 | 2022 | 192 | 2.430 |
Why?
|
| beta-Lactamases | 9 | 2023 | 304 | 2.050 |
Why?
|
| Anti-Bacterial Agents | 24 | 2024 | 7403 | 1.880 |
Why?
|
| Bacteremia | 10 | 2024 | 980 | 1.690 |
Why?
|
| Sepsis | 9 | 2024 | 2587 | 1.550 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 5 | 2020 | 586 | 1.530 |
Why?
|
| Gram-Negative Bacterial Infections | 4 | 2020 | 237 | 1.520 |
Why?
|
| Enterobacteriaceae | 3 | 2021 | 172 | 1.410 |
Why?
|
| Microbial Sensitivity Tests | 15 | 2023 | 1945 | 1.380 |
Why?
|
| Australia | 13 | 2023 | 1276 | 1.330 |
Why?
|
| Mycoses | 2 | 2023 | 386 | 1.280 |
Why?
|
| Streptococcal Infections | 2 | 2024 | 617 | 1.200 |
Why?
|
| Skin Diseases, Bacterial | 2 | 2019 | 68 | 1.190 |
Why?
|
| Gram-Negative Bacteria | 5 | 2023 | 272 | 1.030 |
Why?
|
| Antifungal Agents | 4 | 2023 | 749 | 1.020 |
Why?
|
| Viridans Streptococci | 1 | 2024 | 16 | 0.970 |
Why?
|
| beta-Lactam Resistance | 1 | 2024 | 74 | 0.910 |
Why?
|
| Scedosporium | 1 | 2023 | 10 | 0.900 |
Why?
|
| Flavobacteriaceae Infections | 1 | 2023 | 1 | 0.880 |
Why?
|
| Chryseobacterium | 1 | 2023 | 6 | 0.880 |
Why?
|
| Fungemia | 1 | 2023 | 58 | 0.870 |
Why?
|
| Escherichia coli | 4 | 2023 | 4215 | 0.840 |
Why?
|
| Thyroiditis, Subacute | 1 | 2022 | 11 | 0.820 |
Why?
|
| Arthritis, Reactive | 1 | 2022 | 20 | 0.810 |
Why?
|
| Urethritis | 1 | 2022 | 24 | 0.810 |
Why?
|
| Mycoplasma genitalium | 1 | 2022 | 12 | 0.800 |
Why?
|
| Queensland | 7 | 2023 | 53 | 0.790 |
Why?
|
| Cefotetan | 1 | 2021 | 6 | 0.780 |
Why?
|
| Mycoplasma Infections | 1 | 2022 | 120 | 0.780 |
Why?
|
| Thyrotoxicosis | 1 | 2022 | 85 | 0.770 |
Why?
|
| Cryptococcus neoformans | 1 | 2021 | 121 | 0.730 |
Why?
|
| Cryptococcosis | 1 | 2021 | 104 | 0.730 |
Why?
|
| Hyperammonemia | 1 | 2021 | 76 | 0.730 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2021 | 173 | 0.720 |
Why?
|
| Brain Abscess | 1 | 2021 | 120 | 0.710 |
Why?
|
| Klebsiella pneumoniae | 2 | 2022 | 254 | 0.700 |
Why?
|
| Catheter-Related Infections | 1 | 2023 | 273 | 0.700 |
Why?
|
| Klebsiella Infections | 1 | 2021 | 147 | 0.690 |
Why?
|
| Patient Isolation | 1 | 2020 | 100 | 0.680 |
Why?
|
| Listeria monocytogenes | 1 | 2021 | 248 | 0.660 |
Why?
|
| Q Fever | 1 | 2019 | 38 | 0.650 |
Why?
|
| Mycobacterium avium Complex | 1 | 2019 | 59 | 0.650 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2019 | 76 | 0.630 |
Why?
|
| Streptococcus agalactiae | 1 | 2020 | 337 | 0.630 |
Why?
|
| Cephalosporins | 5 | 2023 | 204 | 0.630 |
Why?
|
| Immunocompromised Host | 1 | 2023 | 856 | 0.600 |
Why?
|
| Staphylococcal Infections | 4 | 2023 | 1406 | 0.600 |
Why?
|
| Typhus, Epidemic Louse-Borne | 1 | 2017 | 2 | 0.600 |
Why?
|
| Escherichia coli Infections | 1 | 2021 | 523 | 0.570 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2022 | 1055 | 0.570 |
Why?
|
| Tick-Borne Diseases | 1 | 2017 | 36 | 0.570 |
Why?
|
| Cytomegalovirus Infections | 1 | 2023 | 831 | 0.560 |
Why?
|
| Leukemia | 1 | 2023 | 1519 | 0.490 |
Why?
|
| Urinary Tract Infections | 1 | 2020 | 812 | 0.450 |
Why?
|
| beta-Lactams | 1 | 2015 | 157 | 0.450 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 981 | 0.450 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2020 | 831 | 0.440 |
Why?
|
| Organ Transplantation | 1 | 2023 | 1150 | 0.440 |
Why?
|
| Brain Diseases | 1 | 2021 | 1541 | 0.410 |
Why?
|
| Diarrhea | 1 | 2019 | 1317 | 0.410 |
Why?
|
| Aspergillus | 2 | 2023 | 92 | 0.400 |
Why?
|
| Drug Resistance, Fungal | 2 | 2023 | 73 | 0.400 |
Why?
|
| Osteomyelitis | 1 | 2015 | 407 | 0.380 |
Why?
|
| Drug Monitoring | 2 | 2022 | 960 | 0.360 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2022 | 1275 | 0.340 |
Why?
|
| Endocarditis, Bacterial | 2 | 2024 | 442 | 0.330 |
Why?
|
| Molecular Epidemiology | 2 | 2021 | 469 | 0.310 |
Why?
|
| Terminal Care | 1 | 2020 | 1750 | 0.310 |
Why?
|
| Humans | 46 | 2024 | 758406 | 0.290 |
Why?
|
| Acute Kidney Injury | 1 | 2019 | 1926 | 0.280 |
Why?
|
| Ceftazidime | 2 | 2022 | 57 | 0.240 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2019 | 2420 | 0.230 |
Why?
|
| Clavulanic Acid | 1 | 2023 | 19 | 0.220 |
Why?
|
| Cefixime | 1 | 2023 | 13 | 0.220 |
Why?
|
| Ureaplasma Infections | 1 | 2023 | 25 | 0.220 |
Why?
|
| Mediastinitis | 1 | 2023 | 49 | 0.220 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 5649 | 0.210 |
Why?
|
| Morganella morganii | 1 | 2022 | 5 | 0.210 |
Why?
|
| Cross Infection | 2 | 2022 | 1432 | 0.210 |
Why?
|
| Sphingomonas | 1 | 2022 | 6 | 0.210 |
Why?
|
| Klebsiella | 1 | 2022 | 52 | 0.210 |
Why?
|
| Shewanella | 1 | 2022 | 12 | 0.200 |
Why?
|
| Azoles | 1 | 2022 | 21 | 0.200 |
Why?
|
| Clinical Trials as Topic | 3 | 2023 | 7985 | 0.190 |
Why?
|
| Cefoxitin | 1 | 2021 | 35 | 0.190 |
Why?
|
| Achromobacter | 1 | 2020 | 8 | 0.190 |
Why?
|
| Macrolides | 1 | 2022 | 205 | 0.180 |
Why?
|
| Saudi Arabia | 1 | 2021 | 209 | 0.180 |
Why?
|
| Fluoroquinolones | 1 | 2022 | 308 | 0.180 |
Why?
|
| Lebanon | 1 | 2021 | 245 | 0.180 |
Why?
|
| Singapore | 1 | 2021 | 287 | 0.180 |
Why?
|
| Spain | 1 | 2021 | 488 | 0.170 |
Why?
|
| Granulocytes | 1 | 2021 | 550 | 0.170 |
Why?
|
| Blood Donors | 1 | 2021 | 343 | 0.160 |
Why?
|
| Cytomegalovirus | 1 | 2023 | 755 | 0.160 |
Why?
|
| Italy | 1 | 2021 | 839 | 0.160 |
Why?
|
| Sigmoidoscopy | 1 | 2019 | 151 | 0.160 |
Why?
|
| Adult | 13 | 2024 | 219935 | 0.150 |
Why?
|
| Drug Resistance, Microbial | 1 | 2021 | 856 | 0.150 |
Why?
|
| Endocarditis | 1 | 2022 | 349 | 0.150 |
Why?
|
| Arachnid Vectors | 1 | 2017 | 24 | 0.150 |
Why?
|
| Rickettsia | 1 | 2017 | 11 | 0.150 |
Why?
|
| Health Literacy | 1 | 2022 | 441 | 0.140 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2021 | 1006 | 0.140 |
Why?
|
| Azabicyclo Compounds | 3 | 2022 | 68 | 0.140 |
Why?
|
| Treatment Failure | 1 | 2023 | 2640 | 0.140 |
Why?
|
| Virulence Factors | 1 | 2020 | 511 | 0.140 |
Why?
|
| Carbapenems | 3 | 2022 | 123 | 0.130 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 1705 | 0.130 |
Why?
|
| Thienamycins | 1 | 2015 | 29 | 0.130 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 694 | 0.130 |
Why?
|
| Middle Aged | 10 | 2024 | 219568 | 0.130 |
Why?
|
| Amikacin | 1 | 2015 | 48 | 0.130 |
Why?
|
| Fosfomycin | 1 | 2015 | 24 | 0.130 |
Why?
|
| Enterobacter cloacae | 1 | 2015 | 22 | 0.130 |
Why?
|
| Neoplasms | 1 | 2024 | 22032 | 0.120 |
Why?
|
| Geography | 1 | 2017 | 660 | 0.120 |
Why?
|
| Staphylococcus epidermidis | 1 | 2015 | 122 | 0.120 |
Why?
|
| Scleroderma, Systemic | 1 | 2019 | 344 | 0.120 |
Why?
|
| Staphylococcus aureus | 4 | 2024 | 1460 | 0.120 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 621 | 0.120 |
Why?
|
| Aged | 9 | 2024 | 168218 | 0.120 |
Why?
|
| Male | 13 | 2024 | 358747 | 0.110 |
Why?
|
| Colectomy | 1 | 2019 | 692 | 0.110 |
Why?
|
| Travel | 1 | 2019 | 785 | 0.110 |
Why?
|
| Infection Control | 1 | 2020 | 982 | 0.110 |
Why?
|
| Phylogeny | 1 | 2020 | 2774 | 0.110 |
Why?
|
| Feces | 1 | 2019 | 1456 | 0.100 |
Why?
|
| Intensive Care Units | 2 | 2023 | 3732 | 0.100 |
Why?
|
| Young Adult | 5 | 2023 | 58808 | 0.100 |
Why?
|
| Echocardiography | 1 | 2024 | 4962 | 0.100 |
Why?
|
| Antitubercular Agents | 1 | 2020 | 1373 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2023 | 3056 | 0.090 |
Why?
|
| Female | 9 | 2024 | 390323 | 0.090 |
Why?
|
| Calcinosis | 1 | 2019 | 1467 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2022 | 58683 | 0.080 |
Why?
|
| Incidence | 2 | 2024 | 21272 | 0.080 |
Why?
|
| Bacterial Proteins | 1 | 2021 | 3824 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2024 | 80168 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2022 | 2020 | 0.060 |
Why?
|
| Adolescent | 4 | 2022 | 87892 | 0.060 |
Why?
|
| Soft Tissue Infections | 1 | 2007 | 167 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 12951 | 0.060 |
Why?
|
| Mycoplasma hominis | 1 | 2023 | 10 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 3812 | 0.050 |
Why?
|
| Ureaplasma | 1 | 2023 | 60 | 0.050 |
Why?
|
| Ureaplasma urealyticum | 1 | 2023 | 39 | 0.050 |
Why?
|
| Hospitalization | 1 | 2023 | 10652 | 0.050 |
Why?
|
| Consent Forms | 1 | 2022 | 55 | 0.050 |
Why?
|
| Pasteurella | 1 | 2022 | 6 | 0.050 |
Why?
|
| DNA Gyrase | 1 | 2022 | 85 | 0.050 |
Why?
|
| Borinic Acids | 1 | 2021 | 2 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 13591 | 0.050 |
Why?
|
| Colistin | 1 | 2021 | 44 | 0.050 |
Why?
|
| Carboxylic Acids | 1 | 2021 | 90 | 0.050 |
Why?
|
| Acinetobacter baumannii | 1 | 2021 | 115 | 0.040 |
Why?
|
| Fungi | 1 | 2022 | 339 | 0.040 |
Why?
|
| Infant | 1 | 2020 | 36055 | 0.040 |
Why?
|
| Risk Factors | 2 | 2022 | 73809 | 0.040 |
Why?
|
| Animals | 3 | 2021 | 167768 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2022 | 1414 | 0.040 |
Why?
|
| Focus Groups | 1 | 2022 | 1384 | 0.040 |
Why?
|
| Informed Consent | 1 | 2022 | 1003 | 0.030 |
Why?
|
| Triazoles | 1 | 2021 | 902 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2022 | 64378 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2022 | 2322 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2024 | 54137 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2024 | 3759 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2022 | 2976 | 0.030 |
Why?
|
| Mycobacterium fortuitum | 1 | 2007 | 6 | 0.020 |
Why?
|
| Mycobacterium ulcerans | 1 | 2007 | 9 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2020 | 8553 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2020 | 5272 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 10146 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 15225 | 0.010 |
Why?
|
| Prognosis | 1 | 2024 | 29557 | 0.010 |
Why?
|
| Child | 2 | 2022 | 79818 | 0.010 |
Why?
|
| Mutation | 1 | 2022 | 29915 | 0.010 |
Why?
|